Compound: Atrasentan
SMILES: O=C(O)[C@H]1[C@@H](N(CC(=O)N(CCCC)CCCC)C[C@@H]1c2cc3OCOc3cc2)c4ccc(OC)cc4
InChIKey: MOTJMGVDPWRKOC-QPVYNBJUSA-N
Synonyms: Atrasentan, 173937-91-2, A-127722, A-147627, (+)-A 127722, V6D7VK2215, 3-Pyrrolidinecarboxylic acid, 4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)-, (2R,3R,4S)-, ABT627, A127722, atrasentanum, DTXSID40870204, 3-Pyrrolidinecarboxylic acid, 4-(1,3-benzodioxol-5-yl)-1-(2-(dibutylamino)-2-oxoethyl)-2-(4-methoxyphenyl)-, (2R,3R,4S)-, RefChem:115499, A-127722.5, DTXCID601509695, A147627, A127722.5, A 127722.5, (2R,3R,4S)-4-(1,3-Benzodioxo-5-yl)-1-(2-(dibutylamino)-2-oxoethyl)-2-(4-methoxyphenyl)-3-pyrrolidinecarboxylic Acid, (2R,3R,4S)-4-(2H-1,3-benzodioxol-5-yl)-1-((dibutylcarbamoyl)methyl)-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic acid, Atrasentan [INN], ABT-627, A 127722, (2R,3R,4S)-4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic acid, 195704-72-4, CHEMBL9194, (2R,3R,4S)-4-(1,3-Benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)-3-pyrrolidinecarboxylic acid, (2S,3R,4S)-4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic acid, rel-(2R,3R,4S)-4-(1,3-Benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)-3-pyrrolidinecarboxylic acid, ABT 627, UNII-V6D7VK2215, ABT 147627, ATRASENTAN [MI], P6FLG98GBJ, ATRASENTAN [VANDF], ATRASENTAN [WHO-DD], SCHEMBL34654, ABT-627;(+)-A 127722;A-147627, GTPL3487, orb1296093, SERT inhibitor compound 8090, SCHEMBL29361546, (+)-A-127722, CHEBI:135810, MOTJMGVDPWRKOC-QPVYNBJUSA-N, (2R,3R,4S)-4-(Benzo[d][1,3]dioxol-5-yl)-1-(2-(dibutylamino)-2-oxoethyl)-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic acid, 4-Benzo[1,3]dioxol-5-yl-1-dibutylcarbamoylmethyl-2-(4-methoxy-phenyl)-pyrrolidine-3-carboxylic acid, EX-A7929, BDBM50051007, EX-A14531, AKOS030255123, DB06199, FA29947, NSC-720763, NCGC00378853-01, NCGC00378853-03, 3-Pyrrolidinecarboxylic acid, 4-(1,3-benzodioxo-5-yl)-1-(2-(dibutylamino)-2-oxoethyl)-2-(4-methoxyphenyl)-, (2R,3R,4S)-, 3-Pyrrolidinecarboxylic acid, 4-(1,3-benzodioxol-5-yl)-1-(2-dibutylamino)-2-oxoethyl)-2-(4-methoxyphenyl)-, (2R-(2alpha,3beta,4alpha))-, DA-50788, ZINC000006658090, HY-114674, CS-0063769, NS00069259, G87012, 4-(4-Fluorophenyl)-2-(piperazin-1-yl)thiazole, Q125083, BRD-K16295392-003-01-3, 2R-(4-methoxyphenyl)-4S(1,N-di(n-butyl)aminocarbonyl-methyl)-pyrrolidine-3R-carboxylic acid, (2r,3r,4s)-(+)-2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(n,n-di(n-butyl)aminocarbonylmethyl)-pyrrolidine-3-carboxylic acid, (2R,3R,4S)-1-((DIBUTYLCARBAMOYL)METHYL)-2-(P-METHOXYPHENYL)-4-(3,4-(METHYLENEDIOXY)PHENYL)-3-PYRROLIDINECARBOXYLIC ACID, (2R,3R,4S)-4-Benzo[1,3]dioxol-5-yl-1-dibutylcarbamoylmethyl-2-(4-methoxy-phenyl)-pyrrolidine-3-carboxylic acid, 3-PYRROLIDINECARBOXYLIC ACID, 4-(1,3-BENZODIOXOL-5-YL)-1-(2-(DIBUTYLAMINO)-2-OXOETHYL)-2-(4-METHOXYPHENYL)-, (2R-(2.ALPHA.,3.BETA.,4.ALPHA.)), 3-Pyrrolidinecarboxylic acid, 4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)-, (2alpha,3beta,4alpha)-, 3-Pyrrolidinecarboxylic acid, 4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)-, (2R,3R,4S)-rel-, 4-(1,3-Benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)-3-pyrrolidinecarboxylic acid, (2R,3R,4S)-rel-, rel-(2R,3R,4S)-4-(Benzo[d][1,3]dioxol-5-yl)-1-(2-(dibutylamino)-2-oxoethyl)-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic acid
Theoretical properties:
molecular_formula: C29H38N2O6
molecular_weight: 510.6 g/mol
exact_mass: 510.27298694 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 1
hydrogen_bond_acceptor_count: 7
rotatable_bond_count: 12
heavy_atom_count: 37
topological_polar_surface_area: 88.5 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
solubility: Slightly soluble
Descriptions:
pubchem: Atrasentan is a member of the class of pyrrolidines that is pyrrolidine substituted by 2-(dibutylamino)-2-oxoethyl, 4-methoxyphenyl, carboxy, and 1,3-benzodioxol-5-yl groups at positions 1, 2, 3, and 4, respectively (the 2R,3R,4S-stereoisomer). It is an endothelin endothelin type A receptor antagonist used to reduce proteinuria in adults with primary immunoglobulin A nephropathy. It has a role as an endothelin A receptor antagonist and a nephroprotective agent. It is a tertiary carboxamide, a monomethoxybenzene, a monocarboxylic acid, a member of pyrrolidines, a member of benzodioxoles, a pyrrolidinecarboxylic acid and a tertiary amino compound.
chebi: A member of the class of pyrrolidines that is pyrrolidine substituted by 2-(dibutylamino)-2-oxoethyl, 4-methoxyphenyl, carboxy, and 1,3-benzodioxol-5-yl groups at positions 1, 2, 3, and 4, respectively (the 2<i>R</i>,3<i>R</i>,4<i>S</i>-stereoisomer). It is an endothelin endothelin type A receptor antagonist used to reduce proteinuria in adults with primary immunoglobulin A nephropathy.
chembl: ATRASENTAN is a small molecule listed in the ChEMBL database and has reached clinical trial phase 3.0.
wikipedia: Atrasentan, sold under the brand name Vanrafia, is a medication used to reduce proteinuria. It is an endothelin receptor antagonist. It is taken by mouth.
Atrasentan was approved for medical use in the United States for IgA nephropathy in April 2025.